AVBP – arrivent biopharma, inc. (US:NASDAQ)
Stock Stats
News
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Truist Financial Corporation to a "strong-buy" rating.
ArriVent BioPharma (NASDAQ:AVBP) was given a new $43.00 price target on by analysts at Truist Financial Corporation.
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: Octagon Capital Advisors LP
Form 10-Q ArriVent BioPharma, Inc. For: Sep 30
Form 8-K ArriVent BioPharma, Inc. For: Nov 10
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: FMR LLC
Form SCHEDULE 13G ArriVent BioPharma, Inc. Filed by: VANGUARD GROUP INC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.